Mainboard · BSE and NSEListed
SYMBIOTEC PHARMALAB LIMITED IPO: dates, price band, lot size, objects of the issue
Get analyst updates on this IPO
Analyst updates come by email.What changed since listing, from SEBI-registered research analysts.
By continuing you agree to the Terms and Privacy policy
Key facts
- Issue price
- ₹988 per share
- groww.in, as of Mon 16 Nov 2026
- Issue size at the upper band
- ₹1,757.00 crore
- Listing date
- Tue 1 Sep 2026
- BSE daily price file for Tue 1 Sep 2026
Timeline (IST)
- OpensMon 24 Aug 2026, 10:00 am IST confirmedRHP dated Tue 18 Aug 2026, page 2
- ClosesThu 27 Aug 2026 confirmedRHP dated Tue 18 Aug 2026, page 2
- UPI mandate cut-offNot stated in the RHP RHP dated Tue 18 Aug 2026
- AllotmentFri 28 Aug 2026 by T+3 schedule
- Refund and unblockMon 31 Aug 2026 by T+3 schedule
- Shares to dematMon 31 Aug 2026 by T+3 schedule
- ListingTue 1 Sep 2026 confirmedBSE daily price file for Tue 1 Sep 2026
Objects of the issue
| Object | Amount |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company | ₹112.50 crore |
| General corporate purposes | Not stated in the RHP |
| Total | Not stated in the RHP |
The ₹1,607.00 crore offer for sale goes to the selling shareholders, not the company. RHP dated Tue 18 Aug 2026, page 138
Company and promoters
As described in the RHP
We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables.
RHP dated Tue 18 Aug 2026, page 218
Promoters
- Satwani Holdings LLP
- 3 individual promoters
RHP dated Tue 18 Aug 2026, page 301
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 36.41% | Not stated in the RHP |
| Public | 63.59% | Not stated in the RHP |
RHP dated Tue 18 Aug 2026, page 130
Financials (restated)
| Item | March 31, 2026 | March 31, 2025 | March 31, 2024 |
|---|---|---|---|
| Revenue from operations | ₹869.15 crore | ₹751.55 crore | ₹716.25 crore |
| Profit after tax | ₹109.90 crore | ₹96.79 crore | ₹100.06 crore |
| Net worth | ₹1,149.73 crore | ₹814.89 crore | ₹715.05 crore |
| Total borrowings | Not stated in the RHP | Not stated in the RHP | Not stated in the RHP |
RHP dated Tue 18 Aug 2026, page 86
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Satwani Holdings LLP | Company | Not announced | Not stated in the RHP |
| Rosewood Investments | Other | Not announced | Not stated in the RHP |
| Individual shareholder | Individual | Not announced | Not stated in the RHP |
| Total offer for sale | ₹1,607.00 crore | ||
RHP dated Tue 18 Aug 2026, page 82
Peer comparison (as in the RHP)
| Name of the company | Face value (₹ per equity share) | Closing price on August 17, 2026 (₹) | Revenue from operations for Fiscal 2026 (in ₹ million) | EPS (₹) for Fiscal 2026 Basic | EPS (₹) for Fiscal 2026 Diluted | NAV (₹ per equity share) for Fiscal 2026 | P/E ratio as on August 17, 2026 | RoNW for Fiscal 2026 (%) |
|---|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab Limited | 2 | N.A. | 8,691.49 | 19.10 | 19.00 | 184.69 | NA | 9.48% |
| Concord Biotech Limited | 1 | 1,513.40 | 10,549.00 | 24.78 | 24.78 | NA | 61.07 | 14.00% |
| Divi's Laboratories Limited | 2 | 8,495.00 | 105,600.00 | 96.75 | 96.75 | 631.00 | 87.80 | 16.50% |
| Cohance Lifesciences Limited | 1 | 444.70 | 22,685.50 | 4.69 | 4.68 | NA | 95.02 | 7.00% |
| Laurus Labs Limited | 2 | 1,799.00 | 68,129.00 | 16.47 | 16.45 | NA | 109.36 | 16.80% |
Reproduced from the RHP dated Tue 18 Aug 2026, page 150; InsightPier adds no figures
Risk factors
97 total- Almost all revenue comes from selling APIs, and the top five APIs make up most of it (RHP page 28)
- Plants face regulator and customer inspections; quality failures could bring regulatory action (RHP page 30)
- Most revenue comes from exports, which carry overseas risks (RHP page 31)
- US tariffs or anti-outsourcing laws could hurt results (RHP page 32)
- A large share of revenue comes from a few key customers (RHP page 33)
Offer document
Allotment and bids
Registrar to the issue: MUFG Intime India Private Limited.
Allotment status was expected on the registrar's site from Fri 28 Aug 2026 and is not yet confirmed. Pick "SYMBIOTEC PHARMALAB LIMITED" from the issue list there.
Subscription (final)
| Category | Shares offered | Shares bid for | Times subscribed |
|---|---|---|---|
| Eligible Employees | 33,407 | 5,37,090 | 16.08× |
| Retail Individual Investors | 62,13,563 | 8,54,50,110 | 13.75× |
| Qualified Institutional Bidders (excluding Anchor Investors) | 35,50,607 | 64,21,33,275 | 180.85× |
| Non Institutional Investors -More than 0.2 Million Upto 1 Million | 8,87,652 | 5,19,87,180 | 58.57× |
| Non Institutional Investors -Above 1 Million | 17,75,304 | 15,58,14,510 | 87.77× |
| Anchor Investors | 53,25,909 | 54,96,165 | 1.03× |
| Total | 1,24,60,533 | 93,59,22,165 | 75.11× |
Total: Excluding anchor investors